[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100146943":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":75,"centralContacts":11,"locations":79,"responsibleParty":91,"collaborators":11,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":11,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":11,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":117,"whyStopped":11,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,16,19,22,25,28],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1","EXPERIMENTAL",null,[13,14,15],"Drug: Treatment A","Drug: Treatment B","Drug: Treatment C",{"label":17,"type":10,"description":11,"interventionNames":18},"Sequence 2",[13,15,14],{"label":20,"type":10,"description":11,"interventionNames":21},"Sequence 3",[14,15,13],{"label":23,"type":10,"description":11,"interventionNames":24},"Sequence 4",[14,13,15],{"label":26,"type":10,"description":11,"interventionNames":27},"Sequence 5",[15,13,14],{"label":29,"type":10,"description":11,"interventionNames":30},"Sequence 6",[15,14,13],[32,37,41,45,47,49,51,53,55,57,59,61,63,65,67,69,71,73],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"DRUG","Treatment A","Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).",[9],{"type":33,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"Treatment B","Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).",[9],{"type":33,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"Treatment C","Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).",[9],{"type":33,"name":34,"description":35,"armGroupLabels":46,"otherNames":11},[17],{"type":33,"name":42,"description":43,"armGroupLabels":48,"otherNames":11},[17],{"type":33,"name":38,"description":39,"armGroupLabels":50,"otherNames":11},[17],{"type":33,"name":38,"description":39,"armGroupLabels":52,"otherNames":11},[20],{"type":33,"name":42,"description":43,"armGroupLabels":54,"otherNames":11},[20],{"type":33,"name":34,"description":35,"armGroupLabels":56,"otherNames":11},[20],{"type":33,"name":38,"description":39,"armGroupLabels":58,"otherNames":11},[23],{"type":33,"name":34,"description":35,"armGroupLabels":60,"otherNames":11},[23],{"type":33,"name":42,"description":43,"armGroupLabels":62,"otherNames":11},[23],{"type":33,"name":42,"description":43,"armGroupLabels":64,"otherNames":11},[26],{"type":33,"name":34,"description":35,"armGroupLabels":66,"otherNames":11},[26],{"type":33,"name":38,"description":39,"armGroupLabels":68,"otherNames":11},[26],{"type":33,"name":42,"description":43,"armGroupLabels":70,"otherNames":11},[29],{"type":33,"name":38,"description":39,"armGroupLabels":72,"otherNames":11},[29],{"type":33,"name":34,"description":35,"armGroupLabels":74,"otherNames":11},[29],[76],{"name":77,"affiliation":5,"role":78},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[80],{"facility":81,"status":11,"city":82,"state":11,"zip":83,"country":82,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":11},"Pfizer Investigational Site","Singapore","188770","SG",{"type":86,"coordinates":87},"Point",[88,89],103.85007,1.28967,{"lat":89,"lon":88},{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":92,"oldOrganization":93},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100146943","phase-1-a-study-to-compare-the-amount-of-tasocitinib-cp-690550-that-is-absorbed-into-the-blood-of-healthy-subjects-following-oral-administration-of-three-different-tablet-versions-of-tasocitinib-cp-690550-100146943",false,"NCT01184092","A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)","Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) Under Fasted Conditions","Inclusion Criteria:\n\n* Healthy male and\u002For female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive.\n* Body Mass Index (BMI) of 17.5 to 30.5 kg\u002Fm2; and a total body weight for males\\>50 kg (110 lbs). For females, total body weight \\>45 kg (99 lbs).\n* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).\n\nExclusion Criteria:\n\n* Evidence of any clinically significant illness, medical condition, or disease.\n* Evidence or history of any clinically significant infections within the past 3 months.\n* Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.",true,"ALL","21 Years","55 Years",{"count":106,"type":107},24,"ESTIMATED","INTERVENTIONAL",[110],"PHASE1","In this study, a 10 mg dose of tasocitinib (CP-690,550) will be given to study subjects on three separate occasions using one of three different tablet formulations (tablet versions) each time. The amount of tasocitinib (CP-690,550) available in the blood following administration of each tablet formulation will be measured and compared. The overall aim of the study is to establish that a similar amount of tasocitinib (CP-690,550) is absorbed into the blood following administration of the same dose of each different tablet formulation.",[113],"Rheumatoid Arthritis",[115,116,113],"Bioequivalence","healthy volunteer study","COMPLETED","2010-10-12",{"date":120,"type":107},"2010-10-14",{"date":122,"type":11},"2010-08",{"date":124,"type":125},"2010-09","ACTUAL",{"name":5,"class":6},1]